Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

After having removed Zepbound from its shortage list in December ... compounded drugs and generic versions of an older Novo Nordisk medicine. Citi analyst Daniel Grosslight said he is less ...

Novo Nordisk’s Ozempic and Lilly’s Mounjaro treat Type 2 diabetes, while Wegovy and Zepbound are anti-obesity medications. The FDA has long warned that compounded medications, which it doesn ...

Zepbound's biggest rival was Novo Nordisk and its semaglutide-based products Wegovy and Ozempic. While Novo and Lilly still dominate the branded GLP-1 drug market, both drugmakers have been ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE ... The higher efficacy of Eli Lilly’s Mounjaro and Zepbound is the reason why NVO has been losing market share. Both companies are ...

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more ... compounding pharmacies and rival Novo Nordisk. The move comes as the competitive ...

While Novo Nordisk stock is less risky now due to its lower valuation, there are still risks. The company faces intense competition from Eli Lilly's Zepbound, which has shown promising results (20 ...

(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from ...